Northland Capital Analyst said this morning “ImmuPharma issued another positive trial update on its flagship drug, Lupuzor, a potential treatment for Lupus. The Phase 3 trial continues to progress to plan, with the drug showing a robust safety profile after over 90% of patients have been dosed for >6 months. We expect the trial to read out in Q1-18. We issued an Update Note (see attached) in which we updated our DCF model—which now indicates a 181p price target (previously 171p). The Company will host an investor presentation today at 11:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.”
- Lupuzor’s pivotal Phase 3 trial is progressing to plan; over 90% of patients (184) have passed the 6 month stage of dosing
- The drug continues to show a robust safety record which is consistent with Lupuzor’s product profile as shown in its previous Phase 2b study
- We expect the trial to read-out top line results in Q1-18
- Lupuzor could achieve multi-billion dollar annual sales as a potential treatment for Lupus. The drug has also recently shown promise in several other major chronic inflammatory indications
- Our updated DCF model indicates a fair value of 181p/share (previously 171p), at which we set our new price target
